company background image
ANTX

AN2 Therapeutics NasdaqGS:ANTX Stock Report

Last Price

US$11.77

Market Cap

US$228.4m

7D

34.7%

1Y

n/a

Updated

11 Aug, 2022

Data

Company Financials +
ANTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANTX Stock Overview

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

AN2 Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AN2 Therapeutics
Historical stock prices
Current Share PriceUS$11.77
52 Week HighUS$23.58
52 Week LowUS$6.88
Beta0
1 Month Change46.76%
3 Month Change-33.43%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-23.57%

Recent News & Updates

Jul 01
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ANTXUS PharmaceuticalsUS Market
7D34.7%-0.6%1.3%
1Yn/a0.7%-11.7%

Return vs Industry: Insufficient data to determine how ANTX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ANTX performed against the US Market.

Price Volatility

Is ANTX's price volatile compared to industry and market?
ANTX volatility
ANTX Average Weekly Movement19.1%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ANTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: Insufficient data to determine ANTX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201722Eric Easomhttps://www.an2therapeutics.com

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc. Fundamentals Summary

How do AN2 Therapeutics's earnings and revenue compare to its market cap?
ANTX fundamental statistics
Market CapUS$228.37m
Earnings (TTM)-US$34.72m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$34.72m
Earnings-US$34.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ANTX perform over the long term?

See historical performance and comparison